Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Bills' Generic Approval "Carve-Out" Needs Refinement, Hatch Says

Executive Summary

Provisions of bills to renew the pediatric exclusivity program which allow for approval of generics despite protected labeling by innovators should be revised, Sen. Orrin Hatch (R-Utah) said.
Advertisement

Related Content

Glucophage Provision Likely To Remain In Final Pediatric Exclusivity Bill
Glucophage Provision Likely To Remain In Final Pediatric Exclusivity Bill
Glucophage Exclusivity Compromise Could Resolve Pediatric Bill Delay
Glucophage Exclusivity Compromise Could Resolve Pediatric Bill Delay
Glucophage Provision In HR 2887 Could Be Breach Of Contract – Bristol
Glucophage Provision In HR 2887 Could Be Breach Of Contract – Bristol
FDA Pediatric Exclusivity Standard Shifts: Is Request “Fairly Met”?
Bristol Glucophage Managed Care Discounts Will Encourage Switches
Pediatric Labeling Would Not Block Generic Approval - House Exclusivity Bill
Pediatric Labeling Would Not Block Generic Approval - House Exclusivity Bill
Advertisement
UsernamePublicRestriction

Register

PS038713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel